Drugs / Radotinib
Radotinib
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01602952 | Jul 2008 → Oct 2012 | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04691661 | Sep 2021 → Sep 2026 overdue | Parkinson disease | Il-Yang Pharm. Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02422719 | Apr 2015 → Mar 2019 | chronic myeloid leukemia | Ulsan University Hospital | Unknown | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT03722420 | Dec 2018 → Mar 2023 overdue | chronic myeloid leukemia | Il-Yang Pharm. Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03459534 | Jun 2018 → Jun 2027 expected | chronic myeloid leukemia | Il-Yang Pharm. Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT01511289 | Aug 2011 → Feb 2015 | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | Il-Yang Pharm. Co., Ltd. | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06461078 Comparator | Jul → Sep 2024 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Radotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01602952 ↗ |
| Known as | IY5511 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297524 ↗ |
| Known as | Radotinib HCl | “Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)” NCT03459534 ↗1“Drug: Radotinib HCl” NCT06461078 ↗ |
| Action | Inhibit | “BCR-ABL1 tyrosine kinase inhibitor” PMID 28939746 ↗ Sep 2017 |
| Modality | Small molecule | “Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI)” PMID 28939746 ↗ Sep 2017 |
| Route | Oral | “oral Radotinib HCl” NCT01602952 ↗ |